Primex Pharmaceuticals AG: Echte innovatie in pediatrische anesthesie sinds propofol
HONGKONG–(BUSINESS WIRE)– Het Zwitserse bedrijf Primex Pharmaceuticals AG kondigt aan de resultaten uit fase II van het onderzoek naar ADV6209 te presenteren op het 16e World Congress of Anaesthesiologists.
Circa zestig procent van de kinderen ondervindt aanzienlijke stress bij perioperatieve sedatie, waardoor ze nerveus, bang en angstig worden en niet willen meewerken. Het uiteindelijke doel is een veilige en effectieve sedatie rond medische ingrepen.
Professor Hervé Dupont, hoofd van de afdeling voor anesthesie en intensieve zorg van het academisch ziekenhuis van Amiens, presenteerde de resultaten van het tweedefaseonderzoek en zijn eigen ervaringen met ADC6209 voor pediatrische sedatie. De resultaten tonen wijzen op een snel sedatief effect en de excellente acceptatie bij pediatrische patiënten als grootste voordelen van de nieuwe formule.
Primex Pharmaceuticals AG: Next real innovation in paediatric anaesthesia since propofol |
|||||
|
HONG KONG–(BUSINESS WIRE)– Swiss company Primex Pharmaceuticals AG announces the presentation of phase II results of ADV6209 at the 16 th World Congress of Anaesthesiologists. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160831005810/en/  Next real innovation in paediatric anaesthesia since propofol (Photo: Business Wire)
Approximately 60% of children experience significant behavioural stress during perioperative or procedural sedation, making them anxious, frightened, phobic and non-cooperative. The ultimate goal is a safe and effective procedural sedation service. Professor Hervé Dupont, Head of the Anaesthesiology and Critical Care Medicine Department at Amiens University Hospital, presented the clinical results from the phase II study and his own experiences of ADV6209 in paediatric sedation. The results show the rapid sedative effect with excellent acceptability by paediatric patients in clinical practice as one of the main advantages of the novel formulation. ADV6209 is an oral solution, and it will be the first paediatric sedative registered in Europe, expected to be on the market next year. “We are excited to bring the next anaesthetic innovation to the market,” Mr. Alan Knox, Head of Global Marketing at Primex comments. “Anaesthesiologists have been asking for a paediatric sedative that is accepted by children and well tolerated to be used by non-anaesthesiologists. For children, there is a large unmet need for pre-anaesthesia and a huge unmet need for procedural sedation, e.g. in emergency and diagnostic procedures.” Kari Sarvanto, President and Co-Founder of Primex Group, added: “Bringing this new solution to the market will be a major step towards making Primex Pharmaceuticals the leading global anaesthesia pharmaceutical company.” About Primex Pharmaceuticals Primex Pharmaceuticals is a fast growing global specialty company spearheading a new lean pharmaceutical business model. Primex aims to become the leading global innovative Anaesthesia company helping patients undergo a wide range of medical procedures. With a portfolio of strong, trusted anaesthesia products including Recofol N (propofol), and the recent acquisition of a novel oral solution pharmaceutical candidate for paediatric anaesthesiology. Primex Pharmaceuticals will continue to identify and acquire new medications that complete the ‘Triad of Anesthesia’. Primex Pharmaceuticals’ global partner network operates in over 40 countries and reaches a population of nearly one billion. The company is headquartered in Zug, Switzerland; all Primex products are manufactured in the EU. Primex Pharmaceuticals has proven underlying business operations and historically strong revenue growth. View source version on businesswire.com: http://www.businesswire.com/news/home/20160831005810/en/ Contacts Primex Pharmaceuticals |
|||||